Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons

Journal of Neuroscience Research

Volumn 71, Issue 4, 2003, Pages 485-495

  Nakamizo, Tomoki ^a   Kawamata, Jun ^b   Yoshida, Kohei ^a   Kawai, Yuko ^a   Kanki, Rie ^a   Sawada, Hideyuki ^a   Kihara, Takeshi ^a   Yamashita, Hirofumi ^a   Shibasaki, Hiroshi ^a   Akaike, Akinori ^a   Shimohama, Shun ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

Amyotrophic lateral sclerosis; cGMP; cGMP dependent protein kinase; Cultured spinal motor neurons; PDE5

Indexed keywords

2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; AMINOPHYLLINE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; DIPYRIDAMOLE; GLUTAMIC ACID; ISOENZYME; KT 5823; MILRINONE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; REACTIVE OXYGEN METABOLITE; ROLIPRAM; UNCLASSIFIED DRUG; VINPOCETINE; ZAPRINAST;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME LOCALIZATION; FETUS; IMMUNOHISTOCHEMISTRY; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD DORSAL HORN; SPINAL CORD MOTONEURON;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; GLUTAMIC ACID; MALE; MOTOR NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; SPINAL CORD;

EID: 0037441463     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10483     Document Type: Article

References (41)

1. Barger SW, Mattson MP. 1996. Induction of neuroprotective κB-dependent transcription by secreted forms of the Alzheimer's β-amyloid precursor. Mol Brain Res 40:116-126.
2. Barger SW, Fiscus RR, Ruth P, Hofmann F, Mattson MP. 1995. Role of cyclic GMP in the regulation of neuronal calcium and survival by secreted forms of beta-amyloid precursor. J Neurochem 64:2087-2096.
3. Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH Jr. 1997. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42:644-654.
4. Beavo JA. 1995. Cyclic nucleotide phosphodiesterase: functional implications of multiple isoforms. Physiol Rev 75:725-748.
5. Bensimon G, Lacomblez L, Meininger V. 1994. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330:585-591.
6. Carriedo SG, Yin HZ, Weiss JH. 1996. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci 16:4069-4079.
7. De Vente J, Asan E, Gambaryan S, Ittersum MM, Axer H, Gallantz K, Lohmann SM, Palkovits M. 2001. Localization of cGMP-dependent protein kinase type II in rat brain. Neuroscience 108:27-49.
8. Dent G, Rabe KF. 1996. Effects of theophylline and non-selective xanthine derivatives on PDE isozymes and cellular function. In: Shudt C, Dent G, Rabe KF, editors. Phosphodiesterase inhibitors. San Diego: Academic Press. p 41-64.
9. Farinelli SE, Park DS, Greene LA. 1996. Nitric oxide delays the death of trophic factor-deprived PC12 cells and sym pathetic neurons by a cGMP-mediated mechanism. J Neurosci 16:2325-2334.
10. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, Phillips SC. 2000. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 97:3702-3707.
11. Fernandez-Tome P, Lizasoain I, Leza JC, Lorenzo P, Moro MA. 1999. Neuroprotective effects of DETA-NONOate, a nitric oxide donor, on hydrogen peroxide-induced neurotoxicity in cortical neurones. Neuropharmacology 38:1307-1315.
12. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH Jr, Beal MF. 1997. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 69:2064-2074.
13. Fisher DA, Smith JF, Pillar JS, St. Denis SH, Cheng JB. 1998. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273:15559-15564.
14. Forloni G, Lucca E, Angeretti N, Chiesa R, Vezzani A. 1997. Neuroprotective effect of somatostatin on nonapoptotic NMDA-induced neuronal death: role of cyclic GMP. J Neurochem 68:319-327.
15. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, Omori K. 1999. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274:18438-18445.
16. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. 1998. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 338:1397-1404.
17. Hetman JM, Soderling SH, Glavas NA, Beavo JA. 2000. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc Natl Acad Sci USA 97:472-476.
18. Keilbach A, Ruth P, Hofmann F. 1992. Detection of cGMP dependent protein kinase isozymes by specific antibodies. Eur J Biochem 208:467-473.
19. Keller JN, Hanni KB, Mattson MP, Markesbery WR. 1998. Cyclic nucleotides attenuate lipid peroxidation-mediated neuron toxicity. Neuroreport 16:3731-3734.
20. Kim Y, Chung H, Kim S, Han J, Yoo Y, Kim K, Lee G, Yun H, Green A, Li J, Simmons RL, Billiar TR. 1999. Nitric oxide protects PC12 cells from serum deprivation-induced apoptosis by cGMP-dependent inhibition of caspase signaling. J Neurosci 19:6740-6747.
21. Kleppisch T, Pfeifer A, Klatt P, Ruth P, Montkowski A, Fassler R, Hofmann F. 1999. Long-term potentiation in the hippocampal CA1 region of mice lacking cGMP-dependent kinases is normal and susceptible to inhibition of nitric oxide synthase. J Neurosci 19:48-55.
22. Kotera J, Fujishige K, Akatsuka H, Imai Y, Yanaka N, Omori K. 1998. Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem 273:26982-26990.
23. Kotera J, Fujishige K, Michibata H, Yuasa K, Kubo A, Nakamura Y, Omori K. 2000a. Characterization and effects of methyl-2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Pharmacol 60:1333-1341.
24. Kotera J, Fujishige K, Omori K. 2000b. Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. J Histochem Cytochem 48:685-693.
25. Lohmann SM, Vaandrager AB, Smolenski A, Walter U, De Jonge HR. 1997. Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci 22:307-312.
26. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, Jones BA, Howard ML, McAllister-Lucas LM, Sonnenburg WK, Francis SH, Corbin JD, Beavo JA, Ferguson K. 1998. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 216:139-147.
27. A inhibitors. Drug News Perspect 6:150-156.
28. Rothstein JD, Van Kammen M, Levey Al, Martin LJ, Kuncl RW. 1995. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38:73-84.
29. Ruth P. 1999. Cyclic GMP-dependent protein kinases: understanding in vivo functions by gene targeting. Pharmacol Ther 82:355-372.
30. Schultheiss D, Muller SV, Nager W, Stief CG, Schlote N, Jonas U, Asvestis C, Johannes S, Munte TF. 2001. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. World J Urol 19:46-50.
31. Sekhar KR, Grondin P, Francis SH, Corbin JD. 1996. Design and synthesis of xanthines and cyclic GMP analogues as potent inhibitors of PDE5. In: Shudt C, Dent G, Rabe KF, editors. Phosphodiesterase inhibitors. San Diego: Academic Press. p 135-146.
32. Serafin WE. 1996. Drugs used in the treatment of asthma. In: Hardman JG, Limbird LE, editors-in-chief. Goodman & Gilman's the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill. p 659-682.
33. Shaw PJ, Ince PG, Falkous G, Mantle D. 1995. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol 38: 691-695.
34. Soderling SH, Beavo JA. 2000. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12:174-179.
35. Soderling SH, Bayuga SJ, Beavo JA. 1998. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci USA 95:8991-8996.
36. Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. 1999. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 46:129-131.
37. Urushitani M, Shimohama S, Kihara T, Sawada H, Akaike A, Ibi M, Inoue R, Kitamura Y, Taniguchi T, Kimura J. 1998. Mechanism of selective motor neuronal death after exposure of spinal cord to glutamate: involvement of glutamate-induced nitric oxide in motor neuron toxicity and nonmotor neuron protection. Ann Neurol 44:796-807.
38. Urushitani M, Inoue R, Nakamizo T, Sawada H, Shibasaki H, Shimohama S. 2000. Neuroprotective effect of cyclic GMP against radical-induced toxicity in cultured spinal motor neurons. J Neurosci Res 61:443-448.
39. Watanabe J, Asaka Y, Nakamura S. 1996. Relationship between immunostaining intensity and antigen content in sections. J Histochem Cytochem 44:1451-1458.
40. Wirtz-Brugger F, Giovanni A. 2000. Guanosine 3′,5′-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: protective effects of propentofylline. Neuroscience 99:737-750.
41. Yuasa K, Kotera J, Fujishige K, Michibata H, Sasaki T, Omori K. 2000. Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J Biol Chem 275:31469-31479.